Intra- and interlaboratory agreement in assessing the in vitro activity of micafungin against common and rare Candida species with the EUCAST, CLSI, and Etest methods

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 6173-6178

  Meletiadis, J ^a,b   Geertsen, E ^c   Curfs Breuker, I ^c   Meis, J F ^b,c,d   Mouton, J W ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ANALYTICAL PARAMETERS; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA FERMENTATI; CANDIDA GLABRATA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA TROPICALIS; CLINICAL AND LABORATORY STANDARDS INSTITUTE; CONTROLLED STUDY; EPSILOMETER TEST; EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING; IN VITRO STUDY; LABORATORY TEST; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YARROWIA LIPOLYTICA; DRUG EFFECTS; LABORATORY; MICROBIAL SENSITIVITY TEST; PROCEDURES; STANDARDS;

ANTIFUNGAL AGENTS; CANDIDA; ECHINOCANDINS; LABORATORIES; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS;

EID: 84992608928     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01027-16     Document Type: Article

References (16)

1. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19-37. http://dx.doi.org/10.1111/1469-0691.12039.
2. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18:53-67. http://dx.doi.org/10.1111/1469-0691.12041.
3. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic. J Clin Microbiol 51:2571-2581. http://dx.doi.org/10.1128/JCM.00308-13.
4. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3nd ed. CLSI document M27-A3. CLSI, Wayne, PA.
5. EUCAST. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 14:398-405. http://dx.doi.org/10.1111/j.1469-0691.2007.01935.x.
6. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN. 2010. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol 48:1592-1599. http://dx.doi.org/10.1128/JCM.02445-09.
7. Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Jones RN. 2014. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Diagn Microbiol Infect Dis 79:198-204. http://dx.doi.org/10.1016/j.diagmicrobio.2014.03.004.
8. Meletiadis J, Arabatzis M, Bompola M, Tsiveriotis K, Hini S, Petinaki E, Velegraki A, Zerva L. 2011. Comparative evaluation of three commercial identification systems using common and rare bloodstream yeast isolates. J Clin Microbiol 49:2722-2727. http://dx.doi.org/10.1128/JCM.01253-10.
9. Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F, Govender NP, Colombo AL, Meis JF, Chowdhary A. 2016. Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-off-light mass spectrometry and amplified fragment length polymorphism. Clin Microbiol Infect 22:277.e1-277.e9. http://dx.doi.org/10.1016/j.cmi.2015.10.022.
10. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W; EUCAST-AFST. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
11. Montagna MT, Lovero G, Coretti C, Martinelli D, De Giglio O, Iatta R, Balbino S, Rosato A, Caggiano G. 2015. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute broth microdilution methods. BMC Microbiol 15:106. http://dx.doi.org/10.1186/s12866-015-0442-4.
12. Marcos-Zambrano LJ, Escribano P, Rueda C, Zaragoza O, Bouza E, Guinea J. 2013. Comparison between the EUCAST procedure and the Etest for determination of the susceptibility of Candida species isolates to micafungin. Antimicrob Agents Chemother 57:5767-5770. http://dx.doi.org/10.1128/AAC.01032-13.
13. Bougnoux ME, Dannaoui E, Accoceberry I, Angoulvant A, Bailly E, Botterel F, Chevrier S, Chouaki T, Cornet M, Dalle F, Datry A, Dupuis A, Fekkar A, Gangneux JP, Guitard J, Hennequin C, LeGovic Y, Le Pape P, Maubon D, Ranque S, Sautour M, Sendid B, Chandenier J. 2016. Multicenter comparison of the Etest and EUCAST for antifungal susceptibility testing of Candida isolates to micafungin. Antimicrob Agents Chemother 60:5088-5091. http://dx.doi.org/10.1128/AAC.00630-16.
14. Espinel-Ingroff A, Canton E, Pelaez T, Peman J. 2011. Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates. Diagn Microbiol Infect Dis 70:54-59. http://dx.doi.org/10.1016/j.diagmicrobio.2010.12.010.
15. Dannaoui E, Lortholary O, Raoux D, Bougnoux ME, Galeazzi G, Lawrence C, Moissenet D, Poilane I, Hoinard D, Dromer F. 2008. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother 52:778-781. http://dx.doi.org/10.1128/AAC.01140-07.
16. Odds FC, Motyl M, Andrade R, Bille J, Cantón E, Cuenca-Estrella M, Davidson A, Durussel C, Ellis D, Foraker E, Fothergill AW, Ghannoum MA, Giacobbe RA, Gobernado M, Handke R, Laverdière M, Lee-Yang W, Merz WG, Ostrosky-Zeichner L, Pemán J, Perea S, Perfect JR, Pfaller MA, Proia L, Rex JH, Rinaldi MG, Rodriguez-Tudela J-L, Schell WA, Shields C, Sutton DA, Verweij PE, Warnock DW. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 42:3475-3482. http://dx.doi.org/10.1128/JCM.42.8.3475-3482.2004.